Conflict of interest reporting by authors involved in promotion of off-label drug use: an analysis of journal disclosures.
Litigation documents reveal that pharmaceutical companies have paid physicians to promote off-label uses of their products through a number of different avenues. It is unknown whether physicians and scientists who have such conflicts of interest adequately disclose such relationships in the scientif...
Main Authors: | Aaron S Kesselheim, Bo Wang, David M Studdert, Jerry Avorn |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS Medicine |
Online Access: | http://europepmc.org/articles/PMC3413710?pdf=render |
Similar Items
-
Disclosure of the Author’s Conflict of Interest: Why?
by: Anastasiya S. Ostrovskaya
Published: (2016-12-01) -
Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints.
by: Aaron S Kesselheim, et al.
Published: (2011-04-01) -
An Uninformative Truth: The Logic of Amarin's Off-Label Promotion.
by: Spencer Phillips Hey, et al.
Published: (2016-03-01) -
The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine.
by: Bo Wang, et al.
Published: (2017-01-01) -
Clinicians' contributions to the development of coronary artery stents: a qualitative study of transformative device innovation.
by: Aaron S Kesselheim, et al.
Published: (2014-01-01)